BERGENBIO HOSTING VIRTUAL R&D DAY

Agenda
(times in CET)

13:00  Introduction - Richard Godfrey, Chief Executive Officer, BerGenBio

Presentations from independent AXL experts, followed by Q&A sessions led by Jim Lorens, Chief Scientific Officer and Hani Gabra, Chief Medical Officer at BerGenBio

13:10  AXL in AML/MDS – Professor Sonja Loges, Director, Department of Personalised Oncology, University Hospital Mannheim and Division of Personalised Medical Oncology, German Cancer Research Center - DKFZ (Heidelberg, Germany)

13:40  AXL in lung cancer – Dr Matthew Krebs, Clinical Senior Lecturer in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust (Manchester, UK)

14:10  AXL and viruses/COVID-19 – Professor Wendy Maury, Professor of Microbiology and Immunology, University of Iowa (Iowa City, USA)

14:40  AXL in fibrosis/IPF – Professor Cory Hogaboam, Professor of Medicine, Cedars-Sinai Medical Center (Los Angeles, USA)

15:10  Bemcentinib clinical development plan – Hani Gabra, Chief Medical Officer, BerGenBio

15:25  Concluding remarks – Richard Godfrey, Chief Executive Officer, BerGenBio